The company’s platform is called GeneTAC, which develops small molecules that can regulate gene expressions up or down ...

The FDA’s nod for suzetrigine bolsters confidence in the pharmaceutical industry’s strategy to target sodium channels.

U.S. officials have approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated ...

A new pain relief drug, suzetrigine, is a prescription pill that’s taken every 12 hours after a larger starter dose. It will be sold under the brand name Journavx.

Today, the U.S. Food and Drug Administration (FDA) gave its approval to Vertex Pharmaceuticals' (NASDAQ: NASDAQ:VRTX) Journavx (suzetrigine) 50 milligram oral tablets. This new drug is a non-opioid ...

Emerging drug-resistant strains are posing significant challenges to the global fight against tuberculosis (TB) and it is a critical task to detect treatment failure as early as possible.

The U.S. Food and Drug Administration (FDA) recently issued two new guidance documents governing details of the Accelerated Approval ...

Since taking office for his second term on Jan. 20, 2025, President Donald Trump has issued a series of executive orders (EOs) aimed at ...

Supporting the decriminalization and study of psychedelics is a bold but necessary step forward. Now is the time to prioritize science over stigma and embrace a progress-based approach to drug policy, ...

Global biopharmaceutical manufacturing firm Rentschler Biopharma will shutter its United Kingdom facility as the ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Ethris announces promising phase 1 results for ETH47, its mRNA therapy for uncontrolled asthma. The inhaled treatment showed strong safety and efficacy, with plans for a phase 2 trial in 2025.